转化医学杂志2025，Vol.14Issue(3)：41-44,4.DOI:10.3639/j.issn.2095-3097.2025.03.009
地舒单抗联合碳酸钙D3及骨化三醇对老年骨质疏松患者骨密度及骨代谢指标影响的研究
Study on the Effects of Combined Use of Denosumab,Calcium Carbonate D3,and Calcitriol on Bone Density and Bone Metabolism Indicators in Elderly Patients with Osteoporosis
摘要
Abstract
Objective To investigate the clinical efficacy of denosumab,calcium carbonate D3,and calcitriol in elder-ly patients with osteoporosis.Methods A total of 98 elderly patients with osteoporosis admitted to Hebei PetroChina Central Hospital from January 2021 to January 2023 were enrolled.Patients were randomly divided into a control group(n=49)and an observation group(n=49)using a random number table.The control group received calcium carbonate D3 and calcitriol,while the observation group received additional denosumab.Post-treatment comparisons included bone mineral density,bone metab-olism indicators,lumbar pain,lumbar dysfunction,and adverse reactions.Results The observation group showed significantly higher overall efficacy than the control group(P<0.05).Post-treatment lumbar spine bone mineral density(0.82±0.17)g/cm2 and hip bone mineral density(0.78±0.17)g/cm2 in the observation group were significantly higher than those in the control group(0.68±0.14)g/cm2 and(0.63±0.14)g/cm2.Additionally,the levels of bone alkaline phosphatase(114.12±11.85)U/L,type I collagen carboxyl-terminal peptide(575.23±50.84)pg/mL,tartrate-resistant acid phosphatase 5b(3.63±0.97)U/L,and β-collagen special sequence(0.23±0.11)μg/L in the observation group were significantly lower than those in the control group(207.58±12.35)U/L,(612.13±62.03)pg/mL,(5.93±1.11)U/L,and(0.36±0.13)μg/L.Meanwhile,the osteocalcin level(5.25±0.76)μg/L in the observation group was higher than that in the control group(3.53±0.63)μg/L,with all differences be-ing statistically significant(P<0.05).The Visual Analogue Scale(VAS)score and Oswestry Disability Index(ODI)score in the observation group were significantly lower than those in the control group(P<0.05).However,there was no statistically signifi-cant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Denosumab combined with calcium carbonate D3 and calcitriol effectively improved bone mineral density,metabolism markers,pain,and in elderly osteo-porosis patients,demonstrating good safety.关键词
老年骨质疏松/地舒单抗/碳酸钙D3/骨化三醇/不良反应Key words
Elderly osteoporosis/Disumab/Calcium carbonate D3/Calcitriol/Adverse reactions分类
医药卫生引用本文复制引用
闻燕,王悦,李江花,陈嘉琳,缴精精..地舒单抗联合碳酸钙D3及骨化三醇对老年骨质疏松患者骨密度及骨代谢指标影响的研究[J].转化医学杂志,2025,14(3):41-44,4.基金项目
廊坊市科学技术研究与发展计划(2020013134) （2020013134）
